JW Lifescience Corporation (KRX:234080)

Market Cap	200.37B +24.5%
Revenue (ttm)	248.30B +12.2%
Net Income	47.59B +65.1%
EPS	3,073.31 +65.1%
Shares Out	15.48M
PE Ratio	4.21
Forward PE	n/a
Dividend	500.00 (3.93%)
Ex-Dividend Date	Mar 31, 2026

Volume	22,155
Average Volume	66,520
Open	13,000
Previous Close	12,940
Day's Range	12,930 - 13,470
52-Week Range	10,350 - 15,580
Beta	0.32
RSI	48.53
Earnings Date	Mar 18, 2026

About JW Lifescience

JW Lifescience Corporation provides national infusion solutions in South Korea and internationally. The company offers basic intravenous fluid that comprises water, electrolytes, and glucose; nutrient infusion solution that consist of nutrients, such as amino acids, lipids, proteins, vitamins, and minerals; and special infusion solutions. The company was formerly known as JW Co. Ltd. and changed its name to JW Lifescience Corporation in April 2011. JW Lifescience Corporation was founded in 1994 and is based in Dangjin-si, South Korea.

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1994
• Employees: 297
• Stock Exchange: Korea Stock Exchange
• Ticker Symbol: 234080

Financial Performance

In 2024, JW Lifescience's revenue was 222.48 billion, an increase of 7.55% compared to the previous year's 206.86 billion. Earnings were 43.99 billion, an increase of 56.29%.